NasdaqGM:BOLD

Stock Analysis Report

Executive Summary

Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects.

Snowflake

Fundamentals

Flawless balance sheet with moderate growth potential.

Share Price & News

How has Audentes Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0.5%

NasdaqGM:BOLD

1.5%

US Biotechs

0.9%

US Market


1 Year Return

2.9%

NasdaqGM:BOLD

-7.3%

US Biotechs

0.3%

US Market

BOLD outperformed the Biotechs industry which returned -8% over the past year.

BOLD outperformed the Market in United States of America which returned -0.5% over the past year.


Share holder returns

BOLDIndustryMarket
7 Day0.5%1.5%0.9%
30 Day-9.6%2.2%-1.9%
90 Day-9.0%3.5%1.6%
1 Year2.9%2.9%-6.5%-7.3%2.6%0.3%
3 Year131.4%131.4%8.9%5.2%41.0%31.8%
5 Yearn/a6.6%1.6%55.2%38.0%

Price Volatility Vs. Market

How volatile is Audentes Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Audentes Therapeutics undervalued based on future cash flows and its price relative to the stock market?

3.7x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Audentes Therapeutics's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

Audentes Therapeutics's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

Audentes Therapeutics is loss making, we can't compare its value to the US Biotechs industry average.

Audentes Therapeutics is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Audentes Therapeutics, we can't assess if its growth is good value.


Price Based on Value of Assets

Audentes Therapeutics is overvalued based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is Audentes Therapeutics expected to perform in the next 1 to 3 years based on estimates from 12 analysts?

55.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Unable to determine if Audentes Therapeutics is high growth as no revenue estimate data is available.

Audentes Therapeutics's earnings are expected to grow significantly at over 20% yearly.

Unable to compare Audentes Therapeutics's revenue growth to the United States of America market average as no estimate data is available.

Audentes Therapeutics's earnings growth is expected to exceed the United States of America market average.

Audentes Therapeutics's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Audentes Therapeutics will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.


Next Steps

Past Performance

How has Audentes Therapeutics performed over the past 5 years?

-46.9%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Audentes Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Audentes Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Audentes Therapeutics's 1-year growth to the US Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Audentes Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Audentes Therapeutics has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Audentes Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Audentes Therapeutics's financial position?


Financial Position Analysis

Audentes Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Audentes Therapeutics's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Audentes Therapeutics has no debt.

Audentes Therapeutics currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

Low level of unsold assets.

Audentes Therapeutics has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Audentes Therapeutics has sufficient cash runway for 2.4 years based on current free cash flow.

Audentes Therapeutics has sufficient cash runway for 2.1 years if free cash flow continues to grow at historical rates of 31.8% each year.


Next Steps

Dividend

What is Audentes Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Audentes Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Audentes Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Audentes Therapeutics has not reported any payouts.

Unable to verify if Audentes Therapeutics's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Audentes Therapeutics has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of Audentes Therapeutics's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of Audentes Therapeutics's salary, the management and board of directors tenure and is there insider trading?

1.3yrs

Average management tenure


CEO

Matt Patterson (47yo)

6.8yrs

Tenure

US$780,480

Compensation

Mr. Matthew R. Patterson, also known as Matt, has been the Chairman of Audentes Therapeutics Inc., since November 5, 2018 and has been its Director since November 2012. Mr. Patterson co-founded Audentes Th ...


CEO Compensation Analysis

Matt's remuneration is lower than average for companies of similar size in United States of America.

Matt's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

1.3yrs

Average Tenure

52yo

Average Age

The average tenure for the Audentes Therapeutics management team is less than 2 years, this suggests a new team.


Board Age and Tenure

3.4yrs

Average Tenure

59.5yo

Average Age

The tenure for the Audentes Therapeutics board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

SellUS$539,76016 Nov 18
Louis Lange
EntityIndividual
Role
Lead Director
Lead Independent Director
Shares24,000
Max PriceUS$22.49

Ownership Breakdown


Management Team

  • Tom Soloway (52yo)

    Executive VP & CFO

    • Tenure: 3.9yrs
    • Compensation: US$525.31k
  • David Nagler (67yo)

    Senior VP of Human Resources & Corporate Affairs

    • Tenure: 4.5yrs
  • Matt Patterson (47yo)

    Co-Founder

    • Tenure: 6.8yrs
    • Compensation: US$780.48k
  • Mary Newman (60yo)

    Senior Vice President of Regulatory Affairs

    • Tenure: 4.8yrs
  • Natalie Holles (46yo)

    President & COO

    • Tenure: 1.3yrs
    • Compensation: US$1.22m
  • Mark Meltz (45yo)

    Senior VP & General Counsel

    • Tenure: 0.4yrs
  • Eric Mosbrooker (52yo)

    Senior VP & Chief Commercial Officer

    • Tenure: 0.6yrs
  • Fulvio Mavilio

    Senior Vice President of Translational Science

    • Tenure: 0.3yrs
  • Andrew Chang

    Director of Investor Relations

    • Tenure: 0.0yrs
  • Sarah Spencer

    Vice President of Corporate Communications

    • Tenure: 0.3yrs

Board Members

  • Lou Lange (70yo)

    Lead Independent Director

    • Tenure: 0.8yrs
    • Compensation: US$296.54k
  • Matt Patterson (47yo)

    Co-Founder

    • Tenure: 6.8yrs
    • Compensation: US$780.48k
  • Tom Schuetz (58yo)

    Independent Director

    • Tenure: 6.1yrs
    • Compensation: US$298.42k
  • Scott Morrison (61yo)

    Independent Director

    • Tenure: 3.7yrs
    • Compensation: US$305.92k
  • Alan Boyd (64yo)

    Member of Scientific & Clinical Advisory Board

    • Tenure: 3.4yrs
  • Julie Smith (48yo)

    Independent Director

    • Tenure: 2.7yrs
    • Compensation: US$300.30k
  • Alan Beggs

    Member of Scientific & Clinical Advisory Board

    • Tenure: 0.0yrs
  • Deborah Bilder

    Member of Scientific & Clinical Advisory Board

    • Tenure: 3.4yrs
  • Mike Lawlor

    Member of Scientific & Clinical Advisory Board

    • Tenure: 3.4yrs
  • Benedikt Schoser

    Member of Scientific & Clinical Advisory Board

    • Tenure: 3.4yrs

Company Information

Audentes Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Audentes Therapeutics, Inc.
  • Ticker: BOLD
  • Exchange: NasdaqGM
  • Founded: 2012
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.556b
  • Shares outstanding: 45.44m
  • Website: https://www.audentestx.com

Number of Employees


Location

  • Audentes Therapeutics, Inc.
  • 600 California Street
  • 17th Floor
  • San Francisco
  • California
  • 94108
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BOLDNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDJul 2016
22ADB (Deutsche Boerse AG)YesCommon StockDEEURJul 2016

Biography

Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/20 00:46
End of Day Share Price2019/08/19 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.